Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...

(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for ...

14, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today that oral decitabine and ...

05). All 32 patients first received frontline therapy with azacitidine (61.5%), decitabine (14.4%), oral decitabine (1.5%), HMA with venetoclax (11.1%), or other HMA combinations (11.5%).